Phenotyping bronchiectasis based on aetiology, exacerbation characteristics and response to erythromycin. - Phenotyping bronchiectasis over 2 years including a macrolide trial

niversity Hospitals Leicester NHS Trust0 个研究点目标入组 90 人开始时间: 2014年3月13日最近更新: 2020年7月20日

适应症

试验速览

暂无简介。

•Group 1 - 40 participants over 2 years including the intervention
•- Patients who have clinical symptoms suggestive of bronchiectasis confirmed by CT scan.
•- Aged 18-100.
•- Ability to give valid consent.
•- Willingness to attend the hospital every 3 months for 2 years.
•Group 2 - 50 participants for baseline visit only
•- Patients who have clinical symptoms suggestive of bronchiectasis confirmed by CT scan.
•- Aged 18-100.
•- Ability to give valid consent.
•- Willingness to attend the hospital for a one off visit.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 25

•Group 1 - 40 participants over 2 years including the intervention
•- Active TB.
•- Patients under 18 and over 100.
•- Patients who are too unwell to attend visits.
•- Patients with known cystic fibrosis.
•- Patients with traction bronchiectasis secondary to fibrosis.
•- Patients who are unable to consent.
•- Patients already on long term antibiotics.
•- Patients with macrolide allergy / severe intolerance / prolonged QT interval.
•- Patients taking medication with a known interaction with erythromycin where the use is contraindicated, with the exception of simvastatin.
•Group 2 - 50 participants for baseline visit only
•- Active TB.
•- Patients under 18 and over 100.
•- Patients who are too unwell to attend visits.
•- Patients with known cystic fibrosis.
•- Patients with traction bronchiectasis secondary to fibrosis.
•- Patients who are unable to consent.

发起方

niversity Hospitals Leicester NHS Trust